Can Gilead Sciences Rebound in the Second Half of 2016?

- Home
- TZ Newswire
- Business Features
- ETF's
- Futures
- Options
- Real Estate
- Stocks
- TZ Featured Lists
- TZ Latest News
- TZ Resources
Editorial Archives
Editorial Archives

Published in TZ Latest News 25 June, 2016 by The TZ Newswire Staff

Can Gilead Sciences Rebound in the Second Half of 2016?

Biotech

Image source: Getty Images.

What: Shares of the blue-chip biotech Gilead Sciences (NASDAQ: GILD) have now fallen by close to 20% in 2016, according to data from S&P Global Market Intelligence.

See also
- Next Article From the archives: Reality TV in the time of cooling home prices
- Previous Article Landlords look to lure small businesses into big spaces
Editorial Calender

June 2016

M T W T F S S

1 2 3 4 5

6 7 8 9 10 11 12

13 14 15 16 17 18 19

20 21 22 23 24 25 26

27 28 29 30

« May Jul »
Recent Tags

Abnormal Returns Active management Asia Brave New World Business Chart.ly Chicago Board Options Exchange CNBC Commodities and Futures Covestor Day Trading Derivatives Equities Exchange Exchange-traded fund Funds Gawker.com GDP Gold Gold as an investment Gross domestic product High-frequency trading Hong Kong Investing Japan Market maker May 6 2010 flash crash Mutual fund National Association of Home Builders New York Mercantile Exchange Option S&P 500 SEC Standard & Poor Stock Stocks and Bonds Stock trader StockTwits Timothy Sykes Tokyo Trade Twitter U.S. Dollar Index U.S. Securities and Exchange Commission United States dollar

The Traderszone Network

Editorial Archives

Published in TZ Latest News 25 June, 2016 by The TZ Newswire Staff

Can Gilead Sciences Rebound in the Second Half of 2016?

See also

Editorial Calender

Recent Tags